Q2 Earnings Estimate for OPKO Health Issued By HC Wainwright

OPKO Health, Inc. (NASDAQ:OPK) – Research analysts at HC Wainwright lowered their Q2 2025 earnings per share (EPS) estimates for OPKO Health in a research report issued to clients and investors on Thursday, May 1st. HC Wainwright analyst Y. Chen now anticipates that the biotechnology company will earn ($0.10) per share for the quarter, down from their prior forecast of ($0.07). HC Wainwright currently has a “Buy” rating and a $3.00 price objective on the stock. The consensus estimate for OPKO Health’s current full-year earnings is ($0.25) per share. HC Wainwright also issued estimates for OPKO Health’s Q3 2025 earnings at ($0.09) EPS, Q4 2025 earnings at ($0.09) EPS, FY2025 earnings at ($0.37) EPS, Q1 2026 earnings at ($0.09) EPS, Q2 2026 earnings at ($0.09) EPS, Q3 2026 earnings at ($0.09) EPS, Q4 2026 earnings at ($0.08) EPS and FY2026 earnings at ($0.34) EPS.

A number of other brokerages have also recently weighed in on OPK. StockNews.com cut shares of OPKO Health from a “hold” rating to a “sell” rating in a research report on Monday. JPMorgan Chase & Co. initiated coverage on shares of OPKO Health in a research note on Friday, April 25th. They issued a “neutral” rating for the company. Finally, Barrington Research restated an “outperform” rating and set a $2.25 target price on shares of OPKO Health in a research note on Thursday, May 1st. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, OPKO Health currently has an average rating of “Hold” and a consensus target price of $2.75.

OPKO Health Stock Down 5.9 %

OPK stock opened at $1.28 on Monday. The firm has a market cap of $859.58 million, a PE ratio of -6.74 and a beta of 1.42. The company has a debt-to-equity ratio of 0.30, a quick ratio of 2.69 and a current ratio of 2.97. OPKO Health has a one year low of $1.15 and a one year high of $2.04. The firm’s 50 day moving average price is $1.60 and its 200-day moving average price is $1.57.

OPKO Health (NASDAQ:OPK) last posted its quarterly earnings results on Wednesday, April 30th. The biotechnology company reported ($0.10) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.03). OPKO Health had a negative net margin of 18.65% and a negative return on equity of 9.76%. The company had revenue of $149.90 million during the quarter, compared to analyst estimates of $163.13 million. During the same period in the prior year, the business posted ($0.12) EPS. OPKO Health’s revenue for the quarter was down 13.7% compared to the same quarter last year.

Hedge Funds Weigh In On OPKO Health

A number of large investors have recently modified their holdings of the business. Millennium Management LLC boosted its position in shares of OPKO Health by 85.3% in the 4th quarter. Millennium Management LLC now owns 4,588,526 shares of the biotechnology company’s stock worth $6,745,000 after buying an additional 2,112,382 shares in the last quarter. Lazard Asset Management LLC raised its position in OPKO Health by 143.6% during the fourth quarter. Lazard Asset Management LLC now owns 2,548,667 shares of the biotechnology company’s stock worth $3,746,000 after acquiring an additional 1,502,342 shares during the last quarter. Altshuler Shaham Ltd purchased a new stake in shares of OPKO Health in the fourth quarter valued at about $2,082,000. Norges Bank acquired a new stake in shares of OPKO Health in the fourth quarter valued at approximately $1,657,000. Finally, Two Sigma Investments LP grew its position in shares of OPKO Health by 136.1% in the fourth quarter. Two Sigma Investments LP now owns 1,647,567 shares of the biotechnology company’s stock valued at $2,422,000 after purchasing an additional 949,671 shares during the last quarter. 64.63% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at OPKO Health

In related news, CEO Phillip Md Et Al Frost bought 200,000 shares of the company’s stock in a transaction dated Monday, March 17th. The shares were acquired at an average price of $1.74 per share, with a total value of $348,000.00. Following the completion of the acquisition, the chief executive officer now owns 213,501,448 shares in the company, valued at approximately $371,492,519.52. This trade represents a 0.09 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Over the last three months, insiders have acquired 767,434 shares of company stock worth $1,238,312. 49.69% of the stock is owned by company insiders.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.